School of Nursing, Fujian Medical University, No. 1, Xuefu North Road, Fuzhou, Fujian, China.
Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29, Xinquan Road, Fuzhou, Fujian, China.
Eur J Med Res. 2023 Mar 14;28(1):120. doi: 10.1186/s40001-023-01076-9.
Studies suggest that high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV) can prevent reintubation in critically ill patients with a low risk of extubation failure. However, the safety and effectiveness in patients at high risk of extubation failure are still debated. Therefore, we conducted a systematic review and meta-analysis to compare the efficacies of HFNC and NIV in high-risk patients.
We searched eight databases (MEDLINE, Cochrane Library, EMBASE, CINAHL Complete, Web of Science, China National Knowledge Infrastructure, Wan-Fang Database, and Chinese Biological Medical Database) with reintubation as a primary outcome measure. The secondary outcomes included mortality, intensive care unit (ICU) length of stay (LOS), incidence of adverse events, and respiratory function indices. Statistical data analysis was performed using RevMan software.
Thirteen randomized clinical trials (RCTs) with 1457 patients were included. The HFNC and NIV groups showed no differences in reintubation (RR 1.10, 95% CI 0.87-1.40, I = 0%, P = 0.42), mortality (RR 1.09, 95% CI 0.82-1.46, I = 0%, P = 0.54), and respiratory function indices (partial pressure of carbon dioxide [PaCO]: MD - 1.31, 95% CI - 2.76-0.13, I = 81%, P = 0.07; oxygenation index [P/F]: MD - 2.18, 95% CI - 8.49-4.13, I = 57%, P = 0.50; respiratory rate [Rr]: MD - 0.50, 95% CI - 1.88-0.88, I = 80%, P = 0.47). However, HFNC reduced adverse events (abdominal distension: RR 0.09, 95% CI 0.04-0.24, I = 0%, P < 0.01; aspiration: RR 0.30, 95% CI 0.09-1.07, I = 0%, P = 0.06; facial injury: RR 0.27, 95% CI 0.09-0.88, I = 0%, P = 0.03; delirium: RR 0.30, 95%CI 0.07-1.39, I = 0%, P = 0.12; pulmonary complications: RR 0.67, 95% CI 0.46-0.99, I = 0%, P = 0.05; intolerance: RR 0.22, 95% CI 0.08-0.57, I = 0%, P < 0.01) and may have shortened LOS (MD - 1.03, 95% CI - 1.86-- 0.20, I = 93%, P = 0.02). Subgroup analysis by language, extubation method, NIV parameter settings, and HFNC flow rate revealed higher heterogeneity in LOS, PaCO, and Rr.
In adult patients at a high risk of extubation failure, HFNC reduced the incidence of adverse events but did not affect reintubation and mortality. Consequently, whether or not HFNC can reduce LOS and improve respiratory function remains inconclusive.
研究表明,高流量鼻导管(HFNC)和无创通气(NIV)可预防拔管失败风险低的危重症患者再次插管。然而,在拔管失败风险高的患者中,其安全性和有效性仍存在争议。因此,我们进行了一项系统评价和荟萃分析,以比较 HFNC 和 NIV 在高危患者中的疗效。
我们检索了 MEDLINE、Cochrane 图书馆、EMBASE、CINAHL Complete、Web of Science、中国国家知识基础设施、万方数据库和中国生物医学文献数据库 8 个数据库,以再插管为主要结局指标。次要结局包括死亡率、重症监护病房(ICU)住院时间(LOS)、不良事件发生率和呼吸功能指标。使用 RevMan 软件进行统计数据分析。
纳入了 13 项随机临床试验(RCT),共 1457 名患者。HFNC 和 NIV 组在再插管(RR 1.10,95%CI 0.87-1.40,I=0%,P=0.42)、死亡率(RR 1.09,95%CI 0.82-1.46,I=0%,P=0.54)和呼吸功能指标(二氧化碳分压[PaCO]:MD-1.31,95%CI-2.76-0.13,I=81%,P=0.07;氧合指数[P/F]:MD-2.18,95%CI-8.49-4.13,I=57%,P=0.50;呼吸频率[Rr]:MD-0.50,95%CI-1.88-0.88,I=80%,P=0.47)方面无差异。然而,HFNC 降低了不良事件的发生率(腹胀:RR 0.09,95%CI 0.04-0.24,I=0%,P<0.01;误吸:RR 0.30,95%CI 0.09-1.07,I=0%,P=0.06;面部损伤:RR 0.27,95%CI 0.09-0.88,I=0%,P=0.03;谵妄:RR 0.30,95%CI 0.07-1.39,I=0%,P=0.12;肺部并发症:RR 0.67,95%CI 0.46-0.99,I=0%,P=0.05;不耐受:RR 0.22,95%CI 0.08-0.57,I=0%,P<0.01),并可能缩短 LOS(MD-1.03,95%CI-1.86--0.20,I=93%,P=0.02)。按语言、拔管方法、NIV 参数设置和 HFNC 流量进行的亚组分析显示,LOS、PaCO 和 Rr 的异质性较高。
在拔管失败风险高的成年患者中,HFNC 降低了不良事件的发生率,但对再插管和死亡率没有影响。因此,HFNC 是否能降低 LOS 和改善呼吸功能仍不确定。